” The best way to predict the future is to create it “
(Peter Drucker – Professor, author & theoretician)
At macopharma, we believe in innovation to reach our vision to raise the standards of care. From incremental to radical and disruptive we organize with multi-disciplinary experts: our innovation committee.
What is an innovation?
A new or modified entity that performs or redistributes value (AFNOR, ISO 56000)
The degree of novelty can be expressed by the attributes of an innovation (ISO 56000) :
Incremental innovation : progressive changes (ISO 56000)
Gradual, continuous improvements on existing products, services, processes, …
Radical innovation: entirely new or significant changes (ISO 56000)
is at the other end of the value chain compared to incremental innovation
Ex: technological breakthrough that transform industries – can create new market
Disruptive innovation: replaces established offers (ISO 56000)
As one of the main actors in the promotion of platelet concentrates preparation, our mission is to understand customers’ needs and provide solutions to help them produce the most qualitative and safe products. Our observation on the platelets’ pooling process led us to the conclusion that platelet concentrates preparation is currently time-consuming, demanding and complex. In order to complete its offer and optimize platelet preparation process, Macopharma has therefore designed Maconnect, the very first multiple sterile connection device
Its one-step procedure
allows up to
0
connections
The time needed to connect
a pool of Buffy Coat is less than
0
seconds
0
single blade
The very first multiple sterile connection device
Especially designed for pooling operations
Maconnect is a unique and innovative concept, especially designed to optimize, simplify and step up the platelets preparation process, while guaranteeing the preparation of a safe platelet concentrate.
Maconnect is the very first multiple sterile connection device, especially designed for pooling operations.
The MacoSeal Light is the new innovation by Macopharma, a cordless sealer with an extended battery autonomy, a unique compact lightweight shape and an outstanding intuitive sealing button enabling every usage configuration.
The remarkable design of the MacoSeal Light was meant to increase the device capabilities while optimising its ergonomics and reducing manual efforts.
1g
Weight
0h00
Complete battery charge
0
Sealings per battery charge
No compromise:
Macopharma bans DEHP, to ensure SAFE and SECURED
blood component solutions to every patient in the world!
More than words, we commit to act and respect our mission:
We support life !
At Macopharma,
we consider Non DEHP
transition as INNOVATION.
we consider Non DEHP
transition as INNOVATION.
Because the value of future bag systems is about safety
we have dedicated a full team of scientific experts to research,
design and develop our new kits as a pure
INNOVATION.
About REACH regulation
REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) is a regulation of the European Union, adopted to improve the protection of human health and the environment from the risks that can be posed by chemicals.(1)
(1) European Chemicals Agency. Understanding REACH. Available at: https://echa.europa.eu/regulations/reach/understanding-reach Accessed July 2022.
About DEHP
Used for decades, DEHP has a positive effect on the red blood cell membrane integrity and reduces the hemolysis. But the listed toxicological effects have to be considered:(1,2)
(1) Horowitz B, Stryker MH, Waldman AA, Woods KR, Gass JD, Drago J. Stabilization of red blood cells by the plasticizer, diethylhexylphthalate. Vox Sang 1985; 48:150-5.
(2) AuBuchon JP, Estep TN, Davey RJ. The effect of the plasticizer di-2-ethylhexyl phthalate on the survival of stored RBCs. Blood 1988; 71:448-52.
CHOOSING the best SOLUTION :
DEHT x PAGGS-M*
DEHT x PAGGS-M*
* Di(ethylhexyl) terephthalate / phosphate-adenine-glucose-guanosin-saline-mannitol
DEHT has an improved safety profile with no reported mutagenic, carcinogenic or reproductive effects(1,2)
PAGGS-M improves red cell concentrate quality parameters with no reported impact on clinical effectiveness or patient safety(3,4)
DEHT versus DEHP
DEHT x PAGGS-M
(1)Kambia Metabolites 2021; 11:94.
(2)Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on the safety of medical devices containing DEHP plasticised PVC or other plasticisers on neonates and other groups possibly at risk (2015 update). 2017.
(3)Larsson L. Vox Sang. 2021;116:60-70
(4)Flegel WA. Br J Haematol. 2014;165(1):3-16.
(5)Graminske, Transfusion 2018; 58:1100-7.
(6)Hess J. Extended Liquid Storage of Red Blood Cells. In: Manning FJ, Sparacino L, Eds. Blood Donors and the Supply of Blood and Blood Products. Washington DC: The National Academies Press, 1996.
performed with